Efficiency of MVP ECG Risk Score for Prediction of Long-Term Atrial Fibrillation in Patients With ICD for Heart Failure With Reduced Ejection Fraction.
Atrial fibrillation
Heart failure
Implantable cardioverter defibrillator
Journal
Korean circulation journal
ISSN: 1738-5520
Titre abrégé: Korean Circ J
Pays: Korea (South)
ID NLM: 101247141
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
22
12
2022
revised:
03
04
2023
accepted:
09
05
2023
medline:
1
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
The morphology-voltage-P-wave duration (MVP) electrocardiography (ECG) risk score is a newly defined scoring system that has recently been used for atrial fibrillation (AF) prediction. The aim of this study was to evaluate the ability of the MVP ECG risk score to predict AF in patients with an implantable cardioverter defibrillator (ICD) and heart failure with reduced ejection fraction in long-term follow-up. The study used a single-center, and retrospective design. The study included 328 patients who underwent ICD implantation in our hospital between January 2010 and April 2021, diagnosed with heart failure. The patients were divided into low, intermediate and high-risk categories according to the MVP ECG risk scores. The long-term development of atrial fibrillation was compared among these 3 groups. The low-risk group included 191 patients, the intermediate-risk group 114 patients, and the high-risk group 23 patients. The long-term AF development rate was 12.0% in the low-risk group, 21.9% in the intermediate risk group, and 78.3% in the high-risk group. Patients in the high-risk group were found to have 5.2 times higher rates of long-term AF occurrence compared to low-risk group. The MVP ECG risk score, which is an inexpensive, simple and easily accessible tool, was found to be a significant predictor of the development of AF in the long-term follow-up of patients with an ICD with heart failure with reduced ejection fraction. This risk score may be used to identify patients who require close follow-up for development and management of AF.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The morphology-voltage-P-wave duration (MVP) electrocardiography (ECG) risk score is a newly defined scoring system that has recently been used for atrial fibrillation (AF) prediction. The aim of this study was to evaluate the ability of the MVP ECG risk score to predict AF in patients with an implantable cardioverter defibrillator (ICD) and heart failure with reduced ejection fraction in long-term follow-up.
METHODS
METHODS
The study used a single-center, and retrospective design. The study included 328 patients who underwent ICD implantation in our hospital between January 2010 and April 2021, diagnosed with heart failure. The patients were divided into low, intermediate and high-risk categories according to the MVP ECG risk scores. The long-term development of atrial fibrillation was compared among these 3 groups.
RESULTS
RESULTS
The low-risk group included 191 patients, the intermediate-risk group 114 patients, and the high-risk group 23 patients. The long-term AF development rate was 12.0% in the low-risk group, 21.9% in the intermediate risk group, and 78.3% in the high-risk group. Patients in the high-risk group were found to have 5.2 times higher rates of long-term AF occurrence compared to low-risk group.
CONCLUSIONS
CONCLUSIONS
The MVP ECG risk score, which is an inexpensive, simple and easily accessible tool, was found to be a significant predictor of the development of AF in the long-term follow-up of patients with an ICD with heart failure with reduced ejection fraction. This risk score may be used to identify patients who require close follow-up for development and management of AF.
Identifiants
pubmed: 37525494
pii: 53.e49
doi: 10.4070/kcj.2022.0353
pmc: PMC10475693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
621-631Informations de copyright
Copyright © 2023. The Korean Society of Cardiology.
Déclaration de conflit d'intérêts
The authors have no financial conflicts of interest.
Références
Cardiol Clin. 2016 May;34(2):255-68
pubmed: 27150174
Eur Heart J. 2022 Feb 10;43(6):440-441
pubmed: 34922348
J Cardiovasc Electrophysiol. 2003 Sep;14(9):940-8
pubmed: 12950538
Can J Cardiol. 2015 Mar;31(3):270-7
pubmed: 25746019
Cardiol Clin. 2009 Feb;27(1):151-61, ix-x
pubmed: 19111771
N Engl J Med. 1980 Aug 7;303(6):322-4
pubmed: 6991948
Circ Res. 2018 Jan 19;122(2):352-368
pubmed: 29348255
Europace. 2020 Jul 1;22(7):1001-1008
pubmed: 32449904
J Electrocardiol. 2020 Jan - Feb;58:113-118
pubmed: 31816563
Heart Rhythm. 2009 Jan;6(1):2-8
pubmed: 18996055
N Engl J Med. 2008 Sep 4;359(10):1009-17
pubmed: 18768944
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
Ann Noninvasive Electrocardiol. 2016 Nov;21(6):580-587
pubmed: 27018476
Europace. 2020 Apr 1;22(4):515-549
pubmed: 31702000
J Am Coll Cardiol. 2008 Apr 8;51(14):1357-65
pubmed: 18387436
Ann Noninvasive Electrocardiol. 2019 Nov;24(6):e12669
pubmed: 31184409
J Am Coll Cardiol. 2011 Oct 18;58(17):1741-9
pubmed: 21996384
J Atr Fibrillation. 2017 Dec 31;10(4):1657
pubmed: 29487682
J Am Coll Cardiol. 2017 Nov 14;70(20):2490-2500
pubmed: 29145948
Adv Med Sci. 2018 Mar;63(1):30-35
pubmed: 28818746
J Am Heart Assoc. 2013 Feb 01;2(1):e005694
pubmed: 23525446
J Am Coll Cardiol. 2019 Aug 27;74(8):1107-1115
pubmed: 31439220
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505